Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. – Cost Effective Supplements

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Quick navigation

Link
Conclusion
Supplements
Functions
Systems

Link to full study

http://www.ncbi.nlm.nih.gov/pubmed/26724101

Conclusion of this study

Our findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy. Randomised controlled trials are warranted to characterise the safety profile and true efficacy of this compound.